Q-omics provides the consensus-scored RPSAP43 profile across patient tissues and cancer cell-line models. RPSAP43 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPSAP43 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, RPSAP43 RNA expression shows 6,713 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, COAD, and STAD as cancer lineages where RPSAP43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP43 survival associations across molecular data types. RPSAP43 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP43 RNA expression–survival associations across cancer types. High RPSAP43 expression shows unfavorable associations in LIHC, ACC and KIRC, but favorable associations in SKCM, LUAD and DLBC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPSAP43 RNA expression.
This table summarizes RPSAP43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP43 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, HNSC, LIHC and ESCA. The COAD box plot shows higher RPSAP43 RNA expression in tumor versus normal tissue (log2 FC = +0.193, t-test p < 0.001).
This table shows molecular features associated with RPSAP43 in patient tissues and cancer cell lines. In patient samples, RPSAP43 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
